Furthermore, KDM1A/LSD1 inhibitors have been tested in clinical trials, for example Iadademstat has been used in combination with azacytidine for the treatment of AML patients showing a manageable safety with promising efficacy [128]. Here, KDM1A is linked to acute myeloid leukemia.